Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group (vol 27, pg 2916, 2009)

被引：0
|
作者：
Bottomley
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 27期
关键词：
D O I：
10.1200/JCO.2009.25.7469
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4630 / 4630
页数：1
相关论文
共 49 条
  • [1] Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
    Bottomley, Andrew
    Coens, Corneel
    Suciu, Stefan
    Santinami, Mario
    Kruit, Willem
    Testori, Alessandro
    Marsden, Jeremy
    Punt, Cornelis
    Sales, Francois
    Gore, Martin
    MacKie, Rona
    Kusic, Zvonko
    Dummer, Reinhard
    Patel, Poulam
    Schadendorf, Dirk
    Spatz, Alain
    Keilholz, Ulrich
    Eggermont, Alexander
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 2916 - 2923
  • [2] Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Testori, Alessandro
    Santinami, Mario
    Kruit, Wim H. J.
    Marsden, Jeremy
    Punt, Cornelis J. A.
    Sales, Francois
    Dummer, Reinhard
    Robert, Caroline
    Schadendorf, Dirk
    Patel, Poulam M.
    de Schaetzen, Gaetan
    Spatz, Alan
    Keilholz, Ulrich
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (31) : 3810 - 3818
  • [3] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
    Eggermont, Alexander M. M.
    Suciu, Stefan
    Santinami, Mario
    Testori, Alessandro
    Kruit, Wim H. J.
    Marsden, Jeremy
    Punt, Cornelis J. A.
    Sales, Francois
    Gore, Martin
    MacKie, Rona
    Kusic, Zvonko
    Dummer, Reinhard
    Hauschild, Axel
    Musat, Elena
    Spatz, Alain
    Keilholz, Ulrich
    [J]. LANCET, 2008, 372 (9633): : 117 - 126
  • [4] Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma:: final results of EORTC 18991, a randomised phase 3 trial
    Eggermont, A. M. M.
    Suciu, S.
    Santinami, M.
    Testori, A.
    Kruit, W.
    Marsden, J.
    Punt, C. J. A.
    Sales, F.
    Gore, M.
    Mckie, R.
    Kusic, V.
    Dummer, R.
    Musat, E.
    Spatz, A.
    Keilholz, U.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 290 - 290
  • [5] Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
    Keilholz, U
    Punt, CJA
    Gore, M
    Kruit, W
    Patel, P
    Lienard, D
    Thomas, J
    Proebstle, TM
    Schmittel, A
    Schadendorf, D
    Velu, T
    Negrier, S
    Kleeberg, U
    Lehman, F
    Suciu, S
    Eggermont, AMM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6747 - 6755
  • [6] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Eggermont, Alexander M. M.
    Bouwhuis, Marna G.
    Kruit, Wim H.
    Testori, Alessandro
    ten Hagen, Timo
    Yver, Antoine
    Xu, Christine
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 671 - 677
  • [7] Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)
    Alexander M. M. Eggermont
    Marna G. Bouwhuis
    Wim H. Kruit
    Alessandro Testori
    Timo ten Hagen
    Antoine Yver
    Christine Xu
    [J]. Cancer Chemotherapy and Pharmacology, 2010, 65 : 671 - 677
  • [8] Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial
    Mohr, Peter
    Hauschild, Axel
    Trefzer, Uwe
    Enk, Alexander
    Tilgen, Wolfgang
    Loquai, Carmen
    Gogas, Helen
    Haalck, Thomas
    Koller, Josef
    Dummer, Reinhard
    Gutzmer, Ralf
    Brockmeyer, Norbert
    Hoelzle, Erhard
    Sunderkoetter, Cord
    Mauch, Cornelia
    Stein, Annette
    Schneider, Lars A.
    Podda, Maurizio
    Goeppner, Daniela
    Schadendorf, Dirk
    Weichenthal, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4077 - +
  • [9] A randomized phase III trial of 1 month versus 1 year adjuvant high-dose interferon alfa-2b in patients with resected high risk melanoma
    Gogas, H.
    Dafni, U.
    Bafaloukos, D.
    Polyzos, A.
    Kokkalis, G.
    Kalofonos, H. P.
    Fountzilas, G.
    Skarlos, D.
    Tsoutsos, D.
    Pectasides, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI – Mel.A.) [ISRCTN75125874]
    Vanna Chiarion-Sileni
    Paola Del Bianco
    Antonella Romanini
    Michele Guida
    Adriano Paccagnella
    Maurizio Dalla Palma
    Emanuele Naglieri
    Ruggero Ridolfi
    Barbara Silvestri
    Maria Michiara
    Gian Luca De Salvo
    [J]. BMC Cancer, 6
12345